Two drug types rarely slowed these pituitary tumors in lab dishes
Original title: Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done with tumor cells in a dish, not in people.
The short version
In lab tests, these drugs slowed growth in only a small share of tumors.
What was studied. Researchers used tumor samples from people with non-working pituitary tumors. They grew the cells in dishes and treated them with several older drugs.
What they found. Overall, the drugs did not slow tumor cell growth. But 13 of the cultures, or 30%, did respond to at least one drug. Tumors that responded to one of the drugs had more of two cell markers.
What this means, and what it doesn't
What it could mean: For most people with these tumors, these drugs look unlikely to help. There is still no reliable way to tell ahead of time who might respond.
What it doesn't mean: This does not mean a new treatment is coming. The work was done with cells in dishes, not in patients. That is the earliest stage of research, far from everyday care. It is not a promise of a cure, and it does not change treatment today.
Source: PubMed, October 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.